Cargando…

Neoantigen personalized vaccine plus anti-PD-1 antibody in cancer patients

Detalles Bibliográficos
Autores principales:	González-Cao, María, Rosell, Rafael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9843347/ https://www.ncbi.nlm.nih.gov/pubmed/36660727 http://dx.doi.org/10.21037/atm-2022-55

Ejemplares similares

Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1
por: Poran, Asaf, et al.
Publicado: (2020)

Personal neoantigen cancer vaccines: The momentum builds
por: Fritsch, Edward F, et al.
Publicado: (2014)

Personalized cancer neoantigen vaccines come of age
por: Chu, Yanhong, et al.
Publicado: (2018)

Engineering neoantigen vaccines to improve cancer personalized immunotherapy
por: Liu, Zaoqu, et al.
Publicado: (2022)

Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
por: Caushi, Justina X., et al.
Publicado: (2021)

The perfect personalized cancer therapy: cancer vaccines against neoantigens
por: Aurisicchio, Luigi, et al.
Publicado: (2018)

Predictive models for response and survival in patients treated with anti-PD-1 monotherapy or with anti-PD-1 and ipilimumab combination: editorial commentary
por: Rotte, Anand
Publicado: (2023)

Neoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy
por: Guo, Yugang, et al.
Publicado: (2018)

Neoadjuvant anti-PD-1 immunotherapy for recurrent glioblastoma
por: Mitchell, Dana, et al.
Publicado: (2019)

PD-1/PD-L1 inhibitor plus chemotherapy versus bevacizumab plus chemotherapy in first-line treatment for non-squamous non-small-cell lung cancer
por: Yu, Hui, et al.
Publicado: (2021)

Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
por: Blass, Eryn, et al.
Publicado: (2021)

Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
por: Rojas, Luis A., et al.
Publicado: (2023)

Sequence of therapies for advanced BRAFV600E/K melanoma
por: Gonzalez-Cao, Maria, et al.
Publicado: (2023)

Durable complete response to neoantigen-loaded dendritic-cell vaccine following anti-PD-1 therapy in metastatic gastric cancer
por: Guo, Zengqing, et al.
Publicado: (2022)

Integration of cancer stemness and neoantigen load to predict responsiveness to anti-PD1/PDL1 therapy
por: Luo, Kunpeng, et al.
Publicado: (2022)

Quantitative spatial profiling of PD-1/PD-L1 interaction in patients with cancer
por: Hakozaki, Taiki
Publicado: (2023)

Computational and Experimental Evaluation of the Immune Response of Neoantigens for Personalized Vaccine Design
por: Malaina, Iker, et al.
Publicado: (2023)

PD-L1 expression associated with better response to EGFR tyrosine kinase inhibitors
por: Rosell, Rafael, et al.
Publicado: (2015)

Personalized neoantigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models
por: Zhang, Rui, et al.
Publicado: (2019)

Personalized neoantigen pulsed dendritic cell vaccine for advanced lung cancer
por: Ding, Zhenyu, et al.
Publicado: (2021)

Neoantigen cancer vaccine augments anti-CTLA-4 efficacy
por: Salvatori, Erika, et al.
Publicado: (2022)

PD-L1 Expression Affects Neoantigen Presentation
por: Okada, Masahiro, et al.
Publicado: (2020)

Author Correction: Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
por: Caushi, Justina X., et al.
Publicado: (2021)

Spleen‐targeted neoantigen DNA vaccine for personalized immunotherapy of hepatocellular carcinoma
por: Wu, Ming, et al.
Publicado: (2023)

Combination TIGIT/PD-1 blockade enhances the efficacy of neoantigen vaccines in a model of pancreatic cancer
por: Peng, Hui, et al.
Publicado: (2022)

Anti-PD1 monotherapy in hepatocellular carcinoma: a step forward or already behind?
por: Catanese, Silvia, et al.
Publicado: (2020)

Personalized Neoantigen-Pulsed DC Vaccines: Advances in Clinical Applications
por: Tang, Lin, et al.
Publicado: (2021)

Mathematical model of a personalized neoantigen cancer vaccine and the human immune system
por: Rodriguez Messan, Marisabel, et al.
Publicado: (2021)

Keynote 407: the combination of pembrolizumab and chemotherapy cracks the shell of squamous cell lung cancer
por: Viteri, Santiago, et al.
Publicado: (2020)

Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
por: Zhang, Yaxiong, et al.
Publicado: (2018)

Prospects of the potential strategies to improve the efficacy of anti‐PD‐1/PD‐L1 therapy
por: Yamaguchi, Hirohito, et al.
Publicado: (2022)

Origins of a Vaccine-Induced, Human Anti-HIV-1 Antibody
por: Julien, Jean-Philippe
Publicado: (2015)

Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, neoantigen vaccination, and Tregs depletion
por: D'Alise, Anna Morena, et al.
Publicado: (2021)

Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) cemiplimab: ongoing and future perspectives in rare genital cancers treatment
por: Gambale, Elisabetta, et al.
Publicado: (2022)

Post‐translationally modified neoantigens: Promising targets for diagnostic strategy of autoimmune diseases
por: Zhai, Yue, et al.
Publicado: (2023)

Comparison of personal and shared frameshift neoantigen vaccines in a mouse mammary cancer model
por: Peterson, Milene, et al.
Publicado: (2020)

Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens
por: Kiyotani, Kazuma, et al.
Publicado: (2018)

Safety and preliminary signs of efficacy with the combination of pembrolizumab plus oxaliplatin and S-1 in Japanese gastric cancer patients
por: Alsina, Maria, et al.
Publicado: (2020)

Targeting PD-1/PD-L1 in lung cancer: current perspectives
por: González-Cao, María, et al.
Publicado: (2015)

Personalized neoantigen vaccine combined with PD-1 blockade increases CD8(+) tissue-resident memory T-cell infiltration in preclinical hepatocellular carcinoma models
por: Chen, Hengkai, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nu7m7rnqeeu85k0m15uaorhs64